Key facts
- BlackRock, Inc. filed SCHEDULE 13G/A for SAGE THERAPEUTICS INC Common Stock (SAGE).
- Disclosed ownership: 7.2%.
- Date of event: 31 Mar 2025.
BlackRock, Inc. - 31 Mar 2025 SCHEDULE 13G/A Report for SAGE THERAPEUTICS INC Common Stock (SAGE)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Security
- SAGE THERAPEUTICS INC Common Stock
- Symbol
- SAGE
- Shares outstanding
- 61,459,403 shares
- Disclosed Ownership
- 4,425,077 shares
- Ownership
- 7.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Apr 2025, 09:35:30 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Key filing fact
BlackRock, Inc. disclosed 7.2% ownership in SAGE THERAPEUTICS INC Common Stock (SAGE) on 31 Mar 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Apr 2025, 09:35.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7.2% | 4,425,077 | 4,352,283 | 0 | Spencer Fleming | Managing Director |
CIK / CUSIP context first